Claudia Giordano

Via Sergio Pansini, 5, Naples
Naples, 80131, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

Breast cancer risk in female survivors of Hodgkin lymphoma after exposure to non-pegylated liposomal doxorubicin at young adult and adult age: the first real-life series from Southern Italy cancer centers.

Breast cancer risk in female survivors of Hodgkin lymphoma after exposure to non-pegylated liposomal doxorubicin at young adult and adult age: the first real-life series from Southern Italy cancer centers.

Journal: Annals of hematology

Published: June 17, 2026

Early Intensification with bendamustine supercharge plus brentuximab vedotinfollowing failure to obtain complete metabolic remission after two cycles of ABVD inpatients aged ≤60 years with classic Hodgkin lymphoma. Comment on:"Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkinlymphoma: the LYSA real-world experience".

Early Intensification with bendamustine supercharge plus brentuximab vedotinfollowing failure to obtain complete metabolic remission after two cycles of ABVD inpatients aged ≤60 years with classic Hodgkin lymphoma. Comment on:"Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkinlymphoma: the LYSA real-world experience".

Journal: Haematologica

Published: May 30, 2026

Collision Tumor of Merkel Cell Carcinoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Cytological and Flow Cytometric Diagnostic Pitfall.

Collision Tumor of Merkel Cell Carcinoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Cytological and Flow Cytometric Diagnostic Pitfall.

Journal: Diagnostic cytopathology

Published: May 11, 2026

Sutimlimab for Relapsed Cold Agglutinin Disease: Real-Life Evidence of Sustained Response With Extended-Interval Dosing.

Sutimlimab for Relapsed Cold Agglutinin Disease: Real-Life Evidence of Sustained Response With Extended-Interval Dosing.

Journal: European journal of haematology

Published: January 18, 2026

Peripherally inserted central venous catheters for remission induction chemotherapy phase of acute leukemia: a single center experience in severely thrombocytopenic patients.

Peripherally inserted central venous catheters for remission induction chemotherapy phase of acute leukemia: a single center experience in severely thrombocytopenic patients.

Journal: Annals of hematology

Published: January 14, 2026

The progression at 24 months (POD24) induces a high risk of transformation of follicular lymphoma: A systematic biopsy verification.

The progression at 24 months (POD24) induces a high risk of transformation of follicular lymphoma: A systematic biopsy verification.

Journal: British journal of haematology

Published: November 18, 2025

Lipegfilgrastim for primary prophylaxis of febrile neutropenia in patients treated for advanced-stage classical hodgkin lymphoma: successful outcomes from a multicenter cohort study.

Lipegfilgrastim for primary prophylaxis of febrile neutropenia in patients treated for advanced-stage classical hodgkin lymphoma: successful outcomes from a multicenter cohort study.

Journal: Annals of hematology

Published: October 22, 2025

Thrombotic complications of central venous catheterization with peripherally inserted catheters in patients with classical-Hodgkin lymphoma.

Thrombotic complications of central venous catheterization with peripherally inserted catheters in patients with classical-Hodgkin lymphoma.

Journal: HemaSphere

Published: October 19, 2025

Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study.

Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study.

Journal: Hematological oncology

Published: October 18, 2025

Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort.

Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort.

Journal: Blood advances

Published: October 15, 2025

Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.

Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.

Journal: Blood advances

Published: October 15, 2025

Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18-59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real-Life Series From Southern Italy Cancer Centers.

Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18-59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real-Life Series From Southern Italy Cancer Centers.

Journal: European journal of haematology

Published: September 29, 2025

Showing 1-12 of 55

Last Updated: 09/26/2026